Hologic, Inc.
Hologic, Inc. (HOLX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Hologic, Inc. (HOLX), featuring income statements, balance sheets, and cash flow data.
Hologic, Inc. (HOLX) Income Statement & Financial Overview
Explore comprehensive income reports for Hologic, Inc. HOLX, broken down by year and quarter.
Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
---|---|---|---|---|
Revenue | $1.005B | $1.02B | $987.90M | $1.01B |
Cost of Revenue | $623.30M | $446.00M | $430.30M | $443.10M |
Gross Profit | $382.00M | $575.80M | $557.60M | $568.30M |
Gross Profit Ratio | $0.38 | $0.56 | $0.56 | $0.56 |
R&D Expenses | $61.50M | $60.30M | $67.30M | $64.10M |
SG&A Expenses | $274.10M | $281.80M | $249.20M | $240.30M |
Operating Expenses | $384.30M | $350.70M | $327.60M | $304.40M |
Total Costs & Expenses | $1.01B | $792.00M | $757.80M | $747.50M |
Interest Income | $14.90M | $24.20M | $28.40M | $28.40M |
Interest Expense | $29.10M | $30.50M | $31.90M | $31.90M |
Depreciation & Amortization | $48.20M | $74.00M | $74.60M | $72.30M |
EBITDA | -$7.00M | $352.00M | $328.10M | $344.90M |
EBITDA Ratio | -$0.007 | $0.34 | $0.33 | $0.34 |
Operating Income | -$7.00M | $229.80M | $230.10M | $263.90M |
Operating Income Ratio | -$0.007 | $0.22 | $0.23 | $0.26 |
Other Income/Expenses (Net) | -$21.50M | $17.70M | -$8.50M | -$23.20M |
Income Before Tax | -$28.50M | $247.50M | $221.60M | $240.70M |
Income Before Tax Ratio | -$0.03 | $0.24 | $0.22 | $0.24 |
Income Tax Expense | -$11.10M | $46.50M | $43.00M | $46.20M |
Net Income | -$17.40M | $201.00M | $178.60M | $194.50M |
Net Income Ratio | -$0.02 | $0.20 | $0.18 | $0.19 |
EPS | -$0.08 | $0.87 | $0.76 | $0.83 |
Diluted EPS | -$0.08 | $0.87 | $0.76 | $0.82 |
Weighted Avg Shares Outstanding | $225.77M | $230.28M | $233.77M | $234.60M |
Weighted Avg Shares Outstanding (Diluted) | $225.77M | $232.11M | $235.97M | $236.47M |
The company's financials show resilient growth, with revenue advancing from $1.01B in Q3 2024 to $1.005B in Q2 2025. Gross profit remained healthy with margins at 38% in Q2 2025 compared to 56% in Q3 2024. Operating income hit -$7.00M last quarter, sustaining a consistent -1% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$7.00M. Net income dropped to -$17.40M, while earnings per share reached -$0.08. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan